FemasysFEMY
FEMY
About: Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Employees: 71
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
13% more funds holding
Funds holding: 30 [Q1] → 34 (+4) [Q2]
2.65% more ownership
Funds ownership: 17.05% [Q1] → 19.7% (+2.65%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
30% less capital invested
Capital invested by funds: $4.88M [Q1] → $3.42M (-$1.46M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
2,381%
upside
Avg. target
$8
2,381%
upside
High target
$8
2,381%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar | 2,381%upside $8 | Buy Maintained | 11 Aug 2025 |
Financial journalist opinion
Based on 5 articles about FEMY published over the past 30 days
Neutral
GlobeNewsWire
11 hours ago
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 10,434,586 shares of its common stock, or in lieu thereof, pre-funded warrants to purchase up to 11,750,000 shares of its common stock, together with accompanying common warrants to purchase up to an aggregate of 22,184,586 shares of its common stock. The combined public offering price for each share of common stock and accompanying common warrant is $0.36, except for 87,363 shares and accompanying warrants sold to certain officers of the Company at a price of $0.5151 per share and accompanying warrant. The combined offering price of each pre-funded warrant and accompanying common warrant is $0.3599. Each accompanying common warrant will have an exercise price of $0.36, except for the warrants sold to certain officers of the Company which will have an exercise price of $0.5151. Each of the accompanying warrants will be immediately exercisable from the date of issuance and will expire five years from the date of issuance.
Negative
Zacks Investment Research
2 weeks ago
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.21 per share a year ago.
Neutral
The Motley Fool
2 weeks ago
Femasys Revenue Jumps 85 Percent in Q2
Femasys Revenue Jumps 85 Percent in Q2
Neutral
GlobeNewsWire
2 weeks ago
Femasys Announces Second Quarter Financial Results for 2025
-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025.
Neutral
GlobeNewsWire
2 weeks ago
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its first commercial entry into Europe with an order of approximately $400,000 USD for FemBloc Permanent Birth Control in Spain, the first country with an established distribution partnership.
Neutral
GlobeNewsWire
1 month ago
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation. “Securing regulatory approvals in Australia and New Zealand mark another important step in expanding global access to our innovative infertility solutions,” said Kathy Lee-Sepsick, CEO and Founder of Femasys.
Neutral
GlobeNewsWire
2 months ago
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class III FemBloc blended polymer component, marking the first regulatory approval in the world for the FemBloc® System for non-surgical female permanent birth control. After European Medicines Agency (EMA) review, the Notified Body has granted CE mark certification.
Neutral
GlobeNewsWire
2 months ago
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed ® , and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on expanding the U.S. infertility market and building key international partners.
Neutral
GlobeNewsWire
2 months ago
Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
-- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces a partnership with Carolinas Fertility Institute (CFI), one of America's best fertility clinics. Carolinas Fertility Institute will provide the Company's FemaSeed® intratubal insemination product as an infertility treatment option to patients throughout its network in North Carolina.
Neutral
GlobeNewsWire
2 months ago
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. In addition, certain existing institutional stockholders of Femasys and certain of its directors and officers have indicated an interest to purchase shares of common stock in a concurrent private placement.
Charts implemented using Lightweight Charts™